LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild‐type glioblastoma patients

MGMT promoter methylation status is currently the only established molecular prognosticator in IDH wild‐type glioblastoma multiforme (GBM). Therefore, we aimed to discover novel therapy‐associated epigenetic biomarkers. After enrichment for hypermethylated fractions using methyl‐CpG‐immunoprecipitat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2016-07, Vol.139 (2), p.424-432
Hauptverfasser:	Mock, Andreas, Geisenberger, Christoph, Orlik, Christian, Warta, Rolf, Schwager, Christian, Jungk, Christine, Dutruel, Céline, Geiselhart, Lea, Weichenhan, Dieter, Zucknick, Manuela, Nied, Ann‐Katrin, Friauf, Sara, Exner, Janina, Capper, David, Hartmann, Christian, Lahrmann, Bernd, Grabe, Niels, Debus, Jürgen, von Deimling, Andreas, Popanda, Odilia, Plass, Christoph, Unterberg, Andreas, Abdollahi, Amir, Schmezer, Peter, Herold‐Mende, Christel
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over biomarker Biomarkers Brain cancer Brain Neoplasms - genetics Brain Neoplasms - mortality Brain Neoplasms - therapy brain tumor Cancer Chemoradiotherapy Chemotherapy CpG Islands DNA fingerprinting DNA Methylation DNA probes Epigenetics Female Gene Expression Regulation, Neoplastic Genes Genome-Wide Association Study Glioblastoma Glioblastoma - genetics Glioblastoma - mortality Glioblastoma - therapy G‐CIMP Humans Immunoprecipitation Independent study Isocitrate Dehydrogenase - genetics Kaplan-Meier Estimate Male Medical research methylation Middle Aged Mortality Patients Probes Prognosis Promoter Regions, Genetic Radiology Reproducibility of Results Surgery Survival Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	MGMT promoter methylation status is currently the only established molecular prognosticator in IDH wild‐type glioblastoma multiforme (GBM). Therefore, we aimed to discover novel therapy‐associated epigenetic biomarkers. After enrichment for hypermethylated fractions using methyl‐CpG‐immunoprecipitation (MCIp), we performed global DNA methylation profiling for 14 long‐term (LTS; >36 months) and 15 short‐term (STS; 6–10 months) surviving GBM patients. Even after exclusion of the G‐CIMP phenotype, we observed marked differences between the LTS and STS methylome. A total of 1,247 probes in 706 genes were hypermethylated in LTS and 463 probes in 305 genes were found to be hypermethylated in STS patients (p values
ISSN:	0020-7136 1097-0215
DOI:	10.1002/ijc.30069